Gene therapy is at the forefront of medicine that utilizes genetic materials to treat or prevent diseases, including neurodegenerative diseases such as Huntington’s disease (HD). While dysregulation of dopamine transmission plays a key role in HD, little is known about the relationship between dopamine and the principal cause of HD, the production of mutant huntingtin protein due to the limitation on visualization of dopamine dynamics at the spatiotemporal resolution of both neuromodulator release (milliseconds) and boutons (microns).
Creative Biolabs has invited Dr. Markita Landry to walk us through how her team developed a near Infrared Catecholamine nanosensor (nIRCat) and used real-time imaging to find out what drives late-disease decreases in evoked dopamine release, and how to use these findings as optimal therapeutic intervention timepoints for siRNA-based HD therapies.
https://www.creative-biolabs.com/gene-therapy/webinar-towards-optimal-therapeutic-intervention-timepoints-for-gene-therapy.htm
